卡培他滨联合奥沙利铂或伊立替康治疗转移性结直肠癌的疗效与安全性

Efficacy and safety of oxaliplatin or irinotecan combined with capecitabine in the treatment of metastasis colorectal carcinoma

目的评价卡培他滨（CAP）联合奥沙利铂（L—OHP）或伊立替康（CPT-11）治疗转移性结直肠癌的疗效及安全性。方法收治转移性结直肠癌患者66例，其中用CAP＋L—OHP方案治疗者31例，CAP＋CPT-11方案治疗者35例，2组均接受4周期化疗，分析2组患者临床有效率及化疗相关药物不良反应。结果CAP＋L—OPH组客观缓解率（ORR）为19．4％，CAP＋CPT-11组为20．0％，差别无统计学意义（P〉0．05）；CAP＋CPT-11组与CAP＋L—OHP组整体Ⅲ-Ⅳ度不良反应发生率分别为51．6％和60．0％，差别无统计学意义（P〉0．05），但CAP＋CPT-11组腹泻的发生率为22．9％，显著高于L—OHP组3．2％（P〈0．05）。结论CAP联合L—OHP或CPT-11治疗转移性结直肠癌临床疗效无明显差别，但CAP＋CPT-11组严重腹泻发生率较高。

Objective To evaluate the efficacy and safety of oxaliplatin （L -OHP） or irinotecan （ CPT -11 ） combined with capecitabine （CAP） in the treatment of metastasis colorectal carcinoma.Methods Sixty -six patients with metastasis colorectal carcinoma were recruited in this study.There were 31 cases in CAP plus L -OHP group and 35 sub-jects in CAP plus CPT -11 group.All of the included cases were treated with 4 cycles of chemotherapy.The clinical efficacy and chemotherapy related side effects were compared between the two groups .Results The objective response rate （ORR） were 19.4% and 20.0% in the CAP plus L -OHP and CAP plus CPT -11 group respectively without statistical difference （P 〉0.05）.The grade Ⅲ to Ⅳ adverse reactions in the CAP plus CPT -11 group and CAP plus L -OHP group were 51.6% and 60.0%, without statistical differences in two groups （P 〉0.05） .But diarrhea incidence in the CAP plus CPT -11 group （22.9%） was much higher than that in the CAP plus L -OHP group （3.2%） （P 〈0.05）. Conclusion There was no statistical difference on clinical efficacy between the two chemotherapy regimens, but there is a higher incidence of serious diarrhea in CAP plus CPT -11 regimen.